Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology
- PMID: 40374871
- PMCID: PMC12234588
- DOI: 10.1007/s10067-025-07449-1
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology
Abstract
Introduction: Digital ulcers (DU) are one of the most frequent manifestations in systemic sclerosis (SSc). The presence of DU seems to be a sentinel sign of internal organ involvement and is related to a poor prognosis of the disease. The aim of this study was to evaluate the prevalence and the relationship of DU with clinical manifestations/variants in a large SSc cohort from the SPRING registry.
Methods: SSc patients fulfilling the ACR/EULAR 2013 classification criteria without missing data on digital ulcers were enrolled in a cross-sectional study. Logistic regression models were built to test the association between the presence of DU and SSc-related features.
Results: Among 1873 eligible SSc patients, the presence of DU was significantly associated with gastrointestinal involvement (OR 1.88, 2.04 and 1.74; p < 0.001) and serum ATA positivity (OR 2.15; p < 0.001), as well as with telangiectasias, sclerodactyly, digital pitting scar, and calcinosis (OR 1.40, p = 0.005; OR 3.43, p < 0.001, OR 9.12, p < 0.001 and OR 2.77, p < 0.001; respectively). In the multivariable regression models, even after adjustment for covariates, ATA positivity (OR 1.76, p = 0.039), puffy fingers (OR 2.82, p < 0.001), and a higher revEUSTAR-AI (OR 6.63, p < 0.001) emerged as risk factors for the presence of DU. Moreover, a low presence of DU was recorded in SSc patients with a history of previous immunosuppressive treatments (OR 0.53, p = 0.032).
Conclusion: In our Italian SSc cohort, DUs were significantly associated with the presence of puffy fingers, high revEUSTR-AI, and ATA seropositivity. Noteworthy, immunosuppressive treatments were associated with a low rate of DU, suggesting that they might contribute to the prevention of these harmful manifestations. Key Points • Digital ulcers were significantly associated with the presence of puffy fingers, high disease activity, and anti-Scl70 seropositivity. • Immunosuppressive treatments were associated with a low rate of digital ulcers, suggesting that they might contribute to the prevention of these harmful manifestations.
Keywords: Digital ulcers; Immunosuppressive therapy; Systemic sclerosis; Vascular disease.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflicts of interest: Orlandi M, Giuggioli D, Bellando-Randone S, Lubrano E, Lumetti F, Ferri C, Generali E, Rosato E, Bianchi G, Sebastiani GD, Pellegrino G, Murdaca G, Foti R, Visalli E, Zanframundo G, Codullo V, De Angelis R, Riccieri V, Parisi S, Peroni CL, D’Angelo S, Pigatto E, Spinella A, Govoni M, Bagnato G, Agnes C, Cuomo G, Franceschini F, Cavazzana I, Campochiaro C, De Luca G, Bajocchi G, Lazzaroni MG, Iannone F, Cacciapaglia F, Scirè CA, Magnani L, Ariani A,, Dagna L, Girelli F, Zanatta F, Ingegnoli F, De Santis M, Abignano G, Della Rossa A, Caminiti M, Iuliano AM, Ciano G, Beretta L, De Andres I, Giollo A, Saracco A, Di Vico C, Gigante A, Mennillo G, Barsotti S, Pagano Mariano G, Furini F, Vultaggio L, Landolfi G, Fusaro E, Cozzi F, Doria A, Salvarani C and Guiducci S have no conflict of interest to declare. Silvia Laura Bosello received consulting fees and/or honoraria from GSK, Abbvie, Boehringer Ingelheim, Research grants from Gruppo Italiano Lotta alla Sclerodermia (GILS). Edoardo Cipolletta received consulting fees and/or honoraria from Novartis and Horizon Therapeutics; research grants from the Foundation for Research in Rheumatology (FOREUM), congress supports from Eli-Lilly, educational grants from the European Alliance of Associations for Rheumatology (EULAR). Matucci-Cerinic M received fees from Actelion, Janssen, Inventiva, Bayer, Biogen, Boehringer, CSL Behring, Corbus, Galapagos, Mitsubishi, Samsung, Regeneron, Acceleron, MSD, Chemomab, Lilly, Pfizer, Roche.
Figures
References
-
- Denton CP, Khanna D (2017) Systemic sclerosis. Lancet. 10.1016/S0140-6736(17)30933-9
-
- Giuggioli D, Manfredi A, Lumetti F, Colaci M, Ferri C (2018) Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. Autoimmun Rev 17(2):155–164. 10.1016/j.autrev.2017.11.020 - PubMed
-
- Hughes M, Herrick AL (2017) Digital ulcers in systemic sclerosis. Rheumatology (Oxford) 56(1):14–25. 10.1093/rheumatology/kew047 - PubMed
-
- Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). [cited 2015 Sep 10];48 Suppl 3:iii19–24 - PubMed
-
- Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G, Bartoli F, Peruzzi F, Blagojevic J, Matucci-Cerinic M (2015) Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. Rheumatology (Oxford) 54(1):72–76. 10.1093/rheumatology/keu296 - PubMed
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
